Extrait

This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.

Critère d'inclusion

• Narcolepsy ,Cataplexy

Liens

• nct
• ictrp